412 related articles for article (PubMed ID: 21910626)
1. Therapeutic targeting of the interleukin-6 receptor.
Tanaka T; Narazaki M; Kishimoto T
Annu Rev Pharmacol Toxicol; 2012; 52():199-219. PubMed ID: 21910626
[TBL] [Abstract][Full Text] [Related]
2. Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases.
Tanaka T; Narazaki M; Kishimoto T
FEBS Lett; 2011 Dec; 585(23):3699-709. PubMed ID: 21419125
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapeutic implication of IL-6 blockade.
Tanaka T; Kishimoto T
Immunotherapy; 2012 Jan; 4(1):87-105. PubMed ID: 22150003
[TBL] [Abstract][Full Text] [Related]
4. Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases.
Tanaka T; Kishimoto T
Int J Biol Sci; 2012; 8(9):1227-36. PubMed ID: 23136551
[TBL] [Abstract][Full Text] [Related]
5. A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy.
Tanaka T; Narazaki M; Ogata A; Kishimoto T
Semin Immunol; 2014 Feb; 26(1):88-96. PubMed ID: 24594001
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses.
Fujimoto M; Serada S; Mihara M; Uchiyama Y; Yoshida H; Koike N; Ohsugi Y; Nishikawa T; Ripley B; Kimura A; Kishimoto T; Naka T
Arthritis Rheum; 2008 Dec; 58(12):3710-9. PubMed ID: 19035481
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic uses of anti-interleukin-6 receptor antibody.
Kang S; Tanaka T; Kishimoto T
Int Immunol; 2015 Jan; 27(1):21-9. PubMed ID: 25142313
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-6 receptor blockade enhances CD39+ regulatory T cell development in rheumatoid arthritis and in experimental arthritis.
Thiolat A; Semerano L; Pers YM; Biton J; Lemeiter D; Portales P; Quentin J; Jorgensen C; Decker P; Boissier MC; Louis-Plence P; Bessis N
Arthritis Rheumatol; 2014 Feb; 66(2):273-83. PubMed ID: 24504799
[TBL] [Abstract][Full Text] [Related]
9. Evidence for the role of Th17 cell inhibition in the prevention of autoimmune diseases by anti-interluekin-6 receptor antibody.
Mihara M; Ohsugi Y; Kishimoto T
Biofactors; 2009; 35(1):47-51. PubMed ID: 19319845
[TBL] [Abstract][Full Text] [Related]
10. The role of interleukin-6 signalling and its therapeutic blockage in skewing the T cell balance in rheumatoid arthritis.
Schinnerling K; Aguillón JC; Catalán D; Soto L
Clin Exp Immunol; 2017 Jul; 189(1):12-20. PubMed ID: 28369786
[TBL] [Abstract][Full Text] [Related]
11. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers.
Yao X; Huang J; Zhong H; Shen N; Faggioni R; Fung M; Yao Y
Pharmacol Ther; 2014 Feb; 141(2):125-39. PubMed ID: 24076269
[TBL] [Abstract][Full Text] [Related]
12. [IL-6 blockade therapy for inflammatory diseases: current perspectives and future directions].
Tanaka T
Nihon Rinsho Meneki Gakkai Kaishi; 2015; 38(6):433-42. PubMed ID: 27118330
[TBL] [Abstract][Full Text] [Related]
13. Anti-interleukin-6 receptor antibody therapy in rheumatic diseases.
Nakahara H; Nishimoto N
Endocr Metab Immune Disord Drug Targets; 2006 Dec; 6(4):373-81. PubMed ID: 17214583
[TBL] [Abstract][Full Text] [Related]
14. The role and therapeutic targeting of IL-6 in rheumatoid arthritis.
Narazaki M; Tanaka T; Kishimoto T
Expert Rev Clin Immunol; 2017 Jun; 13(6):535-551. PubMed ID: 28494214
[TBL] [Abstract][Full Text] [Related]
15. [Immunotherapy using IL-6 receptor as the target].
Nishimoto N
Nihon Rinsho Meneki Gakkai Kaishi; 2008 Oct; 31(5):399-404. PubMed ID: 18974624
[TBL] [Abstract][Full Text] [Related]
16. Brief report: inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis.
Samson M; Audia S; Janikashvili N; Ciudad M; Trad M; Fraszczak J; Ornetti P; Maillefert JF; Miossec P; Bonnotte B
Arthritis Rheum; 2012 Aug; 64(8):2499-503. PubMed ID: 22488116
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-6 blockade in ocular inflammatory diseases.
Mesquida M; Leszczynska A; Llorenç V; Adán A
Clin Exp Immunol; 2014 Jun; 176(3):301-9. PubMed ID: 24528300
[TBL] [Abstract][Full Text] [Related]
18. Tocilizumab: blockade of interleukin-6 signaling pathway as a therapeutic strategy for inflammatory disorders.
Paul-Pletzer K
Drugs Today (Barc); 2006 Sep; 42(9):559-76. PubMed ID: 17028666
[TBL] [Abstract][Full Text] [Related]
19. Effect of interleukin-6 receptor blockade on the balance between regulatory T cells and T helper type 17 cells in rheumatoid arthritis patients.
Pesce B; Soto L; Sabugo F; Wurmann P; Cuchacovich M; López MN; Sotelo PH; Molina MC; Aguillón JC; Catalán D
Clin Exp Immunol; 2013 Mar; 171(3):237-42. PubMed ID: 23379428
[TBL] [Abstract][Full Text] [Related]
20. Can IL-6 blockade rectify imbalance between Tregs and Th17 cells?
Tanaka T
Immunotherapy; 2013 Jul; 5(7):695-7. PubMed ID: 23829620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
